Integrated Bioinformatics Analysis for the Identification of Key lncRNAs, mRNAs, and Potential Drugs in Clear Cell Renal Cell Carcinomas

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Hsieh JJ, Purdue MP, Signoretti S, et al. Renal cell carcinoma. Nat Rev Dis Primers. 2017;3:17009. doi:10.1038/nrdp.2017.9
   PubMed Web of Science ®Google Scholar
• Baugh EH, Lyskov S, Weitzner BD, et al. Real-time PyMOL visualization for Rosetta and PyRosetta. PLoS One. 2011;6(8):e21931. doi:10.1371/journal.pone.0021931
   PubMed Web of Science ®Google Scholar
• Jonasch E, Gao J, Rathmell WK. Renal cell carcinoma. BMJ. 2014;349:g4797. doi:10.1136/bmj.g4797
   PubMed Web of Science ®Google Scholar
• Moch H, Cubilla AL, Humphrey PA, et al. The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: renal, Penile, and Testicular Tumours. Eur Urol. 2016;70(1):93–105. doi:10.1016/j.eururo.2016.02.029
   PubMed Web of Science ®Google Scholar
• Qu L, Wang ZL, Chen Q, et al. Prognostic value of a long non-coding RNA signature in localized clear cell renal cell carcinoma. Eur Urol. 2018;74(6):756–763. doi:10.1016/j.eururo.2018.07.032
   PubMed Web of Science ®Google Scholar
• Braga EA, Fridman MV, Filippova EA, et al. LncRNAs in the regulation of genes and signaling pathways through miRNA-mediated and other mechanisms in clear cell renal cell carcinoma. Int J Mol Sci. 2021;22(20):11193. doi:10.3390/ijms222011193
   PubMed Web of Science ®Google Scholar
• Shi SJ, Wang LJ, Yu B, et al. LncRNA-ATB promotes trastuzumab resistance and invasion-metastasis cascade in breast cancer. Oncotarget. 2015;6(13):11652–11663. doi:10.18632/oncotarget.3457
   PubMedGoogle Scholar
• Arase M, Horiguchi K, Ehata S, et al. Transforming growth factor-beta-induced lncRNA-Smad7 inhibits apoptosis of mouse breast cancer JygMC(A) cells. Cancer Sci. 2014;105(8):974–982. doi:10.1111/cas.12454
   PubMed Web of Science ®Google Scholar
• Gibb EA, Brown CJ, Lam WL. The functional role of long non-coding RNA in human carcinomas. Mol Cancer. 2011;10:38. doi:10.1186/1476-4598-10-38
   PubMed Web of Science ®Google Scholar
• Han Y, Liu Y, Gui Y, et al. Long intergenic non-coding RNA TUG1 is overexpressed in urothelial carcinoma of the bladder. J Surg Oncol. 2013;107(5):555–559. doi:10.1002/jso.23264
   PubMed Web of Science ®Google Scholar
• Xie HW, Wu QQ, Zhu B, et al. Long noncoding RNA SPRY4-IT1 is upregulated in esophageal squamous cell carcinoma and associated with poor prognosis. Tumour Biol. 2014;35(8):7743–7754. doi:10.1007/s13277-014-2013-y
   PubMedGoogle Scholar
• Charoentong P, Finotello F, Angelova M, et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2017;18(1):248–262. doi:10.1016/j.celrep.2016.12.019
   PubMed Web of Science ®Google Scholar
• Barbie DA, Tamayo P, Boehm JS, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009;462(7269):108–112. doi:10.1038/nature08460
   PubMed Web of Science ®Google Scholar
• Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw. 2010;33(1):1–22. doi:10.18637/jss.v033.i01
   PubMed Web of Science ®Google Scholar
• Green MR, Sambrook J. Precipitation of RNA with Ethanol. Cold Spring Harb Protoc. 2020;2020(3):101717. doi:10.1101/pdb.prot101717
   PubMedGoogle Scholar
• El-Hachem N, Haibe-Kains B, Khalil A, et al. AutoDock and AutoDockTools for protein-ligand docking: beta-site amyloid precursor protein cleaving enzyme 1(BACE1) as a case study. Methods Mol Biol. 2017;1598:391–403. doi:10.1007/978-1-4939-6952-4_20
   PubMedGoogle Scholar
• Liu S, Wang R, Lou Y, et al. Uncovering the mechanism of the effects of pien-tze-huang on liver cancer using network pharmacology and molecular docking. Evid Based Complement Alternat Med. 2020;2020:4863015. doi:10.1155/2020/4863015
   PubMed Web of Science ®Google Scholar
• Sun Q, Chen S, Hou Y, et al. Mutant CDKN2A regulates P16/p14 expression by alternative splicing in renal cell carcinoma metastasis. Pathol Res Pract. 2021;223:153453. doi:10.1016/j.prp.2021.153453
   PubMed Web of Science ®Google Scholar
• Chen D, Chen W, Xu Y, et al. Upregulated immune checkpoint HHLA2 in clear cell renal cell carcinoma: a novel prognostic biomarker and potential therapeutic target. J Med Genet. 2019;56(1):43–49. doi:10.1136/jmedgenet-2018-105454
   PubMed Web of Science ®Google Scholar
• Napolitano L, Orecchia L, Giulioni C, et al. The role of miRNA in the management of localized and advanced renal masses, a narrative review of the literature. Appl Sci. 2023;13(1):275. doi:10.3390/app13010275
   Google Scholar
• Cochetti G, Cari L, Nocentini G, et al. Detection of urinary miRNAs for diagnosis of clear cell renal cell carcinoma. Sci Rep. 2020;10(1):21290. doi:10.1038/s41598-020-77774-9
   PubMed Web of Science ®Google Scholar
• Cochetti G, Cari L, Maulà V, et al. Validation in an Independent Cohort of MiR-122, MiR-1271, and MiR-15b as Urinary biomarkers for the potential early diagnosis of clear cell renal cell carcinoma. Cancers. 2022;14(5):1112. doi:10.3390/cancers14051112
   PubMed Web of Science ®Google Scholar
• Wu Y, Tan C, Weng WW, et al. Long non-coding RNA Linc00152 is a positive prognostic factor for and demonstrates malignant biological behavior in clear cell renal cell carcinoma. Am J Cancer Res. 2016;6(2):285–299.
   PubMed Web of Science ®Google Scholar
• Su H, Sun T, Wang H, et al. Decreased TCL6 expression is associated with poor prognosis in patients with clear cell renal cell carcinoma. Oncotarget. 2017;8(4):5789–5799. doi:10.18632/oncotarget.11011
   PubMedGoogle Scholar
• Klatte T, Rossi SH, Stewart GD. Prognostic factors and prognostic models for renal cell carcinoma: a literature review. World J Urol. 2018;36(12):1943–1952. doi:10.1007/s00345-018-2309-4
   PubMed Web of Science ®Google Scholar
• Zhang Z, Lin E, Zhuang H, et al. Construction of a novel gene-based model for prognosis prediction of clear cell renal cell carcinoma. Cancer Cell Int. 2020;20:27. doi:10.1186/s12935-020-1113-6
   PubMed Web of Science ®Google Scholar
• Di Meo NA, Lasorsa F, Rutigliano M, et al. Renal cell carcinoma as a metabolic disease: an update on main pathways, potential biomarkers, and therapeutic targets. Int J Mol Sci. 2022;23(22):14360. doi:10.3390/ijms232214360
   PubMed Web of Science ®Google Scholar
• Bianchi C, Meregalli C, Bombelli S, et al. The glucose and lipid metabolism reprogramming is grade-dependent in clear cell renal cell carcinoma primary cultures and is targetable to modulate cell viability and proliferation. Oncotarget. 2017;8(69):113502–113515. doi:10.18632/oncotarget.23056
   PubMedGoogle Scholar
• Lucarelli G, Loizzo D, Franzin R, et al. Metabolomic insights into pathophysiological mechanisms and biomarker discovery in clear cell renal cell carcinoma. Expert Rev Mol Diagn. 2019;19(5):397–407. doi:10.1080/14737159.2019.1607729
   PubMed Web of Science ®Google Scholar
• Lucarelli G, Rutigliano M, Sallustio F, et al. Integrated multi-omics characterization reveals a distinctive metabolic signature and the role of NDUFA4L2 in promoting angiogenesis, chemoresistance, and mitochondrial dysfunction in clear cell renal cell carcinoma. Aging. 2018;10(12):3957–3985. doi:10.18632/aging.101685
   PubMedGoogle Scholar
• Lucarelli G, Ferro M, Loizzo D, et al. Integration of lipidomics and transcriptomics reveals reprogramming of the lipid metabolism and composition in clear cell renal cell carcinoma. Metabolites. 2020;10(12):509. doi:10.3390/metabo10120509
   PubMed Web of Science ®Google Scholar
• Di Meo NA, Lasorsa F, Rutigliano M, et al. The dark side of lipid metabolism in prostate and renal carcinoma: novel insights into molecular diagnostic and biomarker discovery. Expert Rev Mol Diagn. 2023;23(4):297–313. doi:10.1080/14737159.2023.2195553
   PubMed Web of Science ®Google Scholar
• Bombelli S, Torsello B, De Marco S, et al. 36-kDa Annexin A3 isoform negatively modulates lipid storage in clear cell renal cell carcinoma cells. Am J Pathol. 2020;190(11):2317–2326. doi:10.1016/j.ajpath.2020.08.008
   PubMed Web of Science ®Google Scholar
• He RQ, Qin MJ, Lin P, et al. Prognostic Significance of LncRNA PVT1 and its potential target gene network in human cancers: a comprehensive inquiry based upon 21 cancer types and 9972 cases. Cell Physiol Biochem. 2018;46(2):591–608. doi:10.1159/000488627
   PubMedGoogle Scholar
• Traversa D, Simonetti G, Tolomeo D, et al. Unravelling similarities and differences in the role of circular and linear PVT1 in cancer and human disease. Br J Cancer. 2021;126:835–850. doi:10.1038/s41416-021-01584-7
   PubMed Web of Science ®Google Scholar
• Zhang MX, Zhang LZ, Fu LM, et al. Positive feedback regulation of lncRNA PVT1 and HIF2alpha contributes to clear cell renal cell carcinoma tumorigenesis and metastasis. Oncogene. 2021;40(37):5639–5650. doi:10.1038/s41388-021-01971-7
   PubMed Web of Science ®Google Scholar
• Chen J, Song Y, Li M, et al. Comprehensive analysis of ceRNA networks reveals prognostic lncRNAs related to immune infiltration in colorectal cancer. BMC Cancer. 2021;21(1):255. doi:10.1186/s12885-021-07995-2
   PubMed Web of Science ®Google Scholar
• Guan X, Liu Z, Zhang J, et al. Myeloid-derived suppressor cell accumulation in renal cell carcinoma is correlated with CCL2, IL-17 and IL-18 expression in blood and tumors. Adv Clin Exp Med. 2018;27(7):947–953. doi:10.17219/acem/70065
   PubMed Web of Science ®Google Scholar
• Vergori L, Martinez MC, Bigot P. Circulating large extracellular vesicles carrying CA9 in the diagnosis and prognosis of clear-cell renal cell carcinoma. Clin Transl Med. 2021;11(3):e358. doi:10.1002/ctm2.358
   PubMed Web of Science ®Google Scholar
• Logsdon DP, Grimard M, Luo M, et al. Regulation of HIF1alpha under Hypoxia by APE1/Ref-1 Impacts CA9 expression: dual targeting in patient-derived 3D pancreatic cancer models. Mol Cancer Ther. 2016;15(11):2722–2732. doi:10.1158/1535-7163.MCT-16-0253
   PubMed Web of Science ®Google Scholar
• Knaup KX, Monti J, Hackenbeck T, et al. Hypoxia regulates the sperm associated antigen 4 (SPAG4) via HIF, which is expressed in renal clear cell carcinoma and promotes migration and invasion in vitro. Mol Carcinog. 2014;53(12):970–978. doi:10.1002/mc.22065
   PubMed Web of Science ®Google Scholar
• Cowman SJ, Fuja DG, Liu XD, et al. Macrophage HIF-1alpha is an independent prognostic indicator in kidney cancer. Clin Cancer Res. 2020;26(18):4970–4982. doi:10.1158/1078-0432.CCR-19-3890
   PubMed Web of Science ®Google Scholar
• Schodel J, Grampp S, Maher ER, et al. Hypoxia, hypoxia-inducible transcription factors, and renal cancer. Eur Urol. 2016;69(4):646–657. doi:10.1016/j.eururo.2015.08.007
   PubMed Web of Science ®Google Scholar
• Lapinskas EJ, Svobodova S, Davis ID, et al. The Ets Transcription Factor ELF5 functions as a tumor suppressor in the kidney. Twin Res Hum Genet. 2011;14(4):316–322. doi:10.1375/twin.14.4.316
   PubMed Web of Science ®Google Scholar
• Lee S, Margolin K. Cytokines in cancer immunotherapy. Cancers. 2011;3(4):3856–3893. doi:10.3390/cancers3043856
   PubMedGoogle Scholar
• Bao Y, Wang Z, Liu B, et al. A feed-forward loop between nuclear translocation of CXCR4 and HIF-1alpha promotes renal cell carcinoma metastasis. Oncogene. 2019;38(6):881–895. doi:10.1038/s41388-018-0452-4
   PubMed Web of Science ®Google Scholar
• O’Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med. 2013;368(2):161–170. doi:10.1056/NEJMra1202117
   PubMed Web of Science ®Google Scholar
• Qi Y, Wang L, Wang K, et al. New mechanistic insights of clear cell renal cell carcinoma from integrated miRNA and mRNA expression profiling studies. Bio Pharmac. 2019;111:821–834. doi:10.1016/j.biopha.2018.12.099
   Google Scholar
• Kitchen DB, Decornez H, Furr JR, et al. Docking and scoring in virtual screening for drug discovery: methods and applications. Nat Rev Drug Discov. 2004;3(11):935–949. doi:10.1038/nrd1549
   PubMed Web of Science ®Google Scholar
• Samuels BL, Hollis DR, Rosner GL, et al. Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a cancer and leukemia group B study. Clin Cancer Res. 1997;3(11):1977–1984.
   PubMed Web of Science ®Google Scholar
• Small J, Washburn E, Millington K, et al. The addition of abemaciclib to sunitinib induces regression of renal cell carcinoma xenograft tumors. Oncotarget. 2017;8(56):95116–95134. doi:10.18632/oncotarget.19618
   PubMedGoogle Scholar
• Chen D, Sun X, Zhang X, et al. Inhibition of the CDK4/6-Cyclin D-Rb pathway by ribociclib augments chemotherapy and immunotherapy in renal cell carcinoma. Biomed Res Int. 2020;2020:9525207. doi:10.1155/2020/9525207
   PubMed Web of Science ®Google Scholar